Payment overview · 2025
General Payments
$17.10
1 reported records · 1 companies
Healthcare provider profile · identity verified
Weldon Fred Butler, MD
Allopathic & Osteopathic Physicians|General Practice · ODESSA, TX · NPI 1417941873
Verified facts
What the public records show
CMS Open Payments records show Weldon Fred Butler, MD received $17.10 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.10 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.10 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 127 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 469 | 121 |
| Methylprednisolone | Methylprednisolone | 427 | 247 |
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 115 |
| Azithromycin | Azithromycin | 309 | 193 |
| Gabapentin | Gabapentin | 273 | 67 |
| Potassium Chloride | Potassium Chloride | 255 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 78 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 229 | 67 |
| Lisinopril | Lisinopril | 224 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 68 |
| Cephalexin | Cephalexin | 211 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 55 |
| Furosemide | Furosemide | 197 | 76 |
| Prednisone | Prednisone | 183 | 132 |
| Amantadine | Amantadine Hcl | 180 | 125 |
| Lorazepam | Lorazepam | 173 | 43 |
| Tramadol Hcl | Tramadol Hcl | 156 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 51 |
| Mounjaro | Tirzepatide | 142 | 16 |
| Sertraline Hcl | Sertraline Hcl | 142 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 21 |
| Meloxicam | Meloxicam | 129 | 36 |
| Eszopiclone | Eszopiclone | 120 | 23 |
| Trazodone Hcl | Trazodone Hcl | 120 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 40 |
| Metformin Hcl | Metformin Hcl | 118 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 114 | 93 |
| Glipizide Er | Glipizide | 112 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 14 |
| Januvia | Sitagliptin Phosphate | 93 | 19 |
| Ozempic | Semaglutide | 92 | 20 |
| Simvastatin | Simvastatin | 90 | 25 |
| Omeprazole | Omeprazole | 88 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 24 |
| Buspirone Hcl | Buspirone Hcl | 77 | 13 |
| Losartan Potassium | Losartan Potassium | 75 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Montelukast Sodium | Montelukast Sodium | 71 | 23 |
| Atenolol | Atenolol | 69 | 21 |
| Anastrozole | Anastrozole | 68 | 24 |
| Estradiol | Estradiol | 68 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 16 |
| Eliquis | Apixaban | 66 | 14 |
| Baclofen | Baclofen | 65 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 23 |
| Celecoxib | Celecoxib | 64 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 47 |
| Temazepam | Temazepam | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 15 |
| Sulindac | Sulindac | 51 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 19 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 11 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 29 |
| Metolazone | Metolazone | 42 | 20 |
| Allopurinol | Allopurinol | 41 | 12 |
| Finasteride | Finasteride | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 13 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 38 | 31 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 21 |
| Fluconazole | Fluconazole | 37 | 19 |
| Amoxicillin | Amoxicillin | 35 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | 13 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Tobramycin | Tobramycin | 33 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 32 | suppressed |
| Glipizide | Glipizide | 31 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | 13 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 20 |
| Acyclovir | Acyclovir | 27 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 27 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | 13 |
| Nystatin | Nystatin | 25 | 13 |
| Ondansetron Odt | Ondansetron | 25 | 19 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.10 · 1 records | Novo Nordisk Inc | Ozempic, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error